First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi, providing real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.
Abstract
Objective
To compare the risk of major adverse cardiovascular events (MACE) between tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi) when initiated as first-line advanced therapy in patients with rheumatoid arthritis (RA).
Methods
Using the Korean nationwide claims database, we identified patients newly diagnosed with RA between 2010 and 2015. Patients who initiated TNFi or JAKi as first-line advanced therapy were selected for analysis. Patients were followed from initiation of TNFi or JAKi through June 2024. The primary outcome was incident MACE, defined as myocardial infarction, ischemic stroke, or coronary revascularization. Multivariable Cox proportional hazards models were applied in the total cohort. We additionally performed propensity score (PS)-matched analyses to address confounding by indication. Prespecified subgroup analyses were conducted according to baseline cardiovascular risk factors.
Results
The study included 6,174 patients (TNFi = 5,152; JAKi = 1,022). The incidence rates of MACE were 4.1 and 3.6 per 1,000 person-years in the TNFi and JAKi groups, respectively. MACE risk did not differ significantly between JAKi and TNFi in the total study cohort (adjusted hazard ratio [HR] 0.636, 95% confidence interval [CI] 0.283 to 1.429) or in the PS-matched population (adjusted HR 0.715, 95% CI 0.187 to 2.739). Results were consistent across all prespecified subgroups, including patients with baseline cardiovascular risk factors.
Conclusion
First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi. These findings provide real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.
In this real-world cohort of older adults with RA, initiation of JAK inhibitors was not associated with higher risks of MACE, VTE, malignancy, or mortality compared with TNF inhibitors.
Betul Ibis, F. Bahar, S. Sheehy et al.· Journal of Rheumatology· 0 citations
BACKGROUND
The cardiovascular safety of Janus kinase inhibitors (JAKi) compared with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) remains debated. We aimed to evaluate the risk of major adverse cardiov...
Objectives This study aims to compare cardiovascular and mortality outcomes of Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) at elevated cardiovascular risk using target trial emulation. Methods Within TriNetX, adults with RA aged ≥50 years and ≥1 cardiovascu...
R. McClenahan, L. Alamlih· Frontiers in Immunology· 0 citations
Findings support proactive cardiovascular risk assessment and optimization in long-term survivors while reinforcing that the excess risk is modest and should not deter use of these life-prolonging therapies.
I. Nardi Agmon, V. Giannakeas, Y. Kaliwal et al.· European Heart Journal· 0 citations
In statin-treated patients with ASCVD, PCSK9i use was associated with a modestly lower 5-year incidence of new-onset AS, and this findings are hypothesis-generating.
AIM
To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia.
METHODS
We conducted a retrospective cohort study using the TriNetX global health re...
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al.· QJM : monthly journal of the...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.